Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer



Status:Terminated
Conditions:Prostate Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:January 19, 2015
End Date:August 17, 2017

Use our guide to learn which trials are right for you!

A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer

This study will be conducted in three parts. Part A is a dose-escalation study to determine
two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate
cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001
through blood sampling. Subjects in Part B will receive one of two doses identified in Part A
to determine which one is more effective, and collect additional pharmacokinetic data. Part C
is an extension for subjects completing either Part A or B.

Parts A and B will include a screening period (up to 28 days) and a 12-week treatment period.
A subject with no serious adverse drug reactions and who is expected to benefit from
continued treatment in the opinion of the investigator will have the opportunity to
participate in the long-term extension (Part C). If the subject is not a candidate for or
chooses not to participate in the long-term extension (Part C), a post-treatment period of 4
weeks will commence that concludes with an end-of-study visit.

Subjects participating in only Part A or Part B will have approximately 9 study site visits
over 18 weeks. Part C will include monthly visits to the study site for 9 months. Thereafter,
visits will occur every 3 months. A subject with stable disease or response may continue
ASN001 treatment with the approval of the investigator; treatment can continue until a
subject experiences an intolerable adverse event (AE) or disease progression, withdraws
consent or until termination of the study by the sponsor. At the end of treatment, a
post-treatment period of 4 weeks will commence that concludes with an end-of-study visit.

Part B of the study will not be completed as enrollment was halted after Part A (Phase 1)

Inclusion Criteria

- Histologically confirmed adenocarcinoma of the prostate.

- Ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone
(LHRH) agonist or antagonist, or bilateral orchiectomy and serum testosterone level <
50 ng/dL (< 0.5 ng/mL, < 1.7 nmol/L) at screening

- Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging
(MRI) or bone scan.

- Progressive disease despite ongoing androgen deprivation therapy.

- Adequate liver, kidney, and bone marrow function

- Life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening

- Patients with prior cytotoxic chemotherapy are eligible to participate if they have
been progression free for at least 12 months since the initiation of cytotoxic
chemotherapy

Exclusion Criteria:

- Patients with rapidly progressive disease who are candidates for other approved
therapies such as docetaxel, abiraterone, and enzalutamide.

- Prior therapy with abiraterone, orteronel, ketoconazole, or any other Cytochrome P450
(CYP) 17 lyase inhibitor; enzalutamide or other experimental androgen receptor
antagonist; or experimental immunotherapy agent.

- History of impaired adrenal gland function

- Any investigational treatments for any condition within 4 weeks prior to the start of
study treatment.

- Therapy with herbal products known to effect PSA, or estrogen within 30 days prior to
the start of study medication

- Known gastrointestinal disease or condition that affects the absorption of ASN001, or
difficulty swallowing large capsules.

- Use of systemic glucocorticoid (eg, prednisone, dexamethasone) within 14 days prior to
the start of study medication

- Major surgery within 30 days of study medication

- Known brain metastasis

- Previous history of another cancer within 5 years, except completely removed basal or
squamous cell skin cancer.

- Serious concurrent medical conditions including: serious heart disease, heart
conduction abnormalities, persistent infection, uncontrolled psychiatric illness,
liver cirrhosis, chronic liver disease, active or symptomatic viral hepatitis, any
other condition that may place the subject at an increased risk or confound the
results of the study.
We found this trial at
6
sites
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Robert Dreicer, M.D.
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Jorge Garcia, M.D.
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Ulka Vaishampayan, M.D.
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Allan J Pantuck, M.D.
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Naomi Haas, M.D.
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Anthony Tolcherr, M.D.
?
mi
from
San Antonio, TX
Click here to add this to my saved trials